RxDoctor Payments Data

Jairo Olivares, MD

Hematology & Oncology · Garland, TXNPI 1770520165

Payments from drug & device makers

$176,357in general payments, 2019–2025

Across 192 payments — averaging $918.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$121K
  • Array Biopharma Inc$43K
  • Astrazeneca UK Limited$10K
  • Merck$185
  • Pfizer$146
  • Incyte Corporation$140
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$2,17990%
  • Education$24610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$176,357 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$248,140
Medicare patients
104
Services billed
15,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →